Valeant Pharmaceutical shares were surging in premarket trading Wednesday, after analysts with Morgan Stanley upgraded their rating on the struggling Canadian drugmaker to Overweight from Neutral, reinstating the rating they last held in September.
Subscribe to TheStreetTV on YouTube:
For more content from TheStreet visit:
Check out all our videos:
Follow TheStreet on Twitter:
Like TheStreet on Facebook:
Follow TheStreet on LinkedIn:
Follow TheStreet on Google+:
source
